Sirona Biochem Corp. · OTC:SRBCF
Sirona Biochem — Investor Presentation (August 2023)
23 slides from Sirona Biochem's investor presentation, August 2023
Slide 1: Investor Presentation August 2023
EN INVESTOR PRESENTATION August 2023 TSX-V: SBM FSE: ZSB | OTC: SRBCF ADVANCING CHEMISTRY. ENHANCING HEALTH
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS Sirona Biochem cautions you that statements included in this presentation that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks a
Slide 3: Table of Contents
TABLE OF CONTENTS Investment Highlights •••••••••••••••• 4 Facilities/M. Partners •••••••••••••••• 16 Share Information •••••••••••••••• 5 Technology •••••••••••••••• 17 Business Model Strategy •••••••••••••••• 6 Management •••••••••••••••• 20 Business Model Success •••••••••••••••• 7 Contact Us •••
Slide 4: Investment Highlights
INVESTMENT HIGHLIGHTS Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Through its wholly-owned French subsidiary TFChem, the Company specialises in stabilising carbohydrate molecules with the goal of improving efficacy and safety. Sirona Bio
Slide 5: Share Information
SHARE INFORMATION TSX VENTURE EXCHANGE SBM OTCQX EXCHANGE SRBCF FRANKFURT STOCK EXCHANGE ZSB FUNDAMENTAL DATA (CAD) SBM TSX-V Shares Outstanding 252,111,526 Shares Fully Diluted 252,223,526 Shares owned by Insiders: 15% $0.12 Share Price (CAD) Market Cap $30,267,000 $0.215 8.9M 10.4M Year High SHARE
Slide 6: Business Model & Strategy
BUSINESS MODEL & STRATEGY Sirona Biochem’s strategy is to license or sell patented compounds to leading global companies in return for up-front fees, milestone fees and ongoing royalty payments. TSX-V: SBM | FSE: ZSB | OTC: SRBCF 6 www.sironabiochem.com
Slide 7: Business Model Success
BUSINESS MODEL SUCCESS Allergan Aesthetics, an AbbVie [NYSE: ABBV] company, signed a global exclusive licensing deal with Sirona Biochem for its library of breakthrough dark-spot corrector compounds, inlcuding TFC-1067 TSX-V: SBM | FSE: ZSB | OTC: SRBCF 7 www.sironabiochem.com
Slide 8: Product Pipeline
PRODUCT PIPELINE Cosmetic Products Pharmaceutical Products Sirona Biochem has invested extensively in developing products to meet the needs of patients and industry partners. The compounds created through the company’s proprietary platform go through rigorous tests and regulatory scrutiny to verify
Slide 9: Cosmetic Products
COSMETIC PRODUCTS Therapeutic Area Compound Status Skincare - Dark spot corrector TFC-1067 & family of • Exclusive global licensing deal with AbbVie (Rx & OTC) dark spot correctors Cell Preservation & Repair Glycoprotein Library • Ongoing lead determination (incl keloid & scar therapy) Skincare - An
Slide 10: Pharmaceutical Products
PHARMACEUTICAL PRODUCTS Therapeutic Area Compound Status Status Diabetes & Other (SGLT2 • In due diligence & discussions with interested parties from the animal health sector TFC-039 inhibitor) • In due diligence & discussion for regional human health license • Undertaking new research with SGLT2 In
Slide 11: Worldwide IP Portfolio
WORLDWIDE IP PORTFOLIO Sirona Biochem has a strong IP portfolio, including a recently filed patent for its breakthrough anti-aging compound TFC-1326, managed by intellectual property law firm Cabinet Regimbeau, Paris France TSX-V: SBM | FSE: ZSB | OTC: SRBCF 11 www.sironabiochem.com
Slide 12: Milestones
MILESTONES Milestones achieved in the last 12 months: Completed successful 12 week clinical study for anti-aging compound TFC-1326 Completed an oversubscribed financing of $1.53M CAD Completed an exclusive, global license with AbbVie for TFC-1067 Completed a first round of testing the antivi
Slide 13: Our Next Big Thing: Anti-Aging - TFC-1326
OUR NEXT BIG THING: Anti-Aging - TFC-1326 TFC-1326 & Compound Library The anti-aging market is forecast to reach $271 Billion by 2024, with anti-wrinkle accounting for 59.3% of the total share. Sirona recently filed a patent for its glycopeptides treatment, which rejuvenates and restores the skin’s
Slide 14: Animal Health - TFC-039
Animal Health - TFC-039 INDUSTRY PROBLEM It’s estimated that 1.7 million cats will develop diabetes. Treatment is needed to manage their condition, often requiring twice-daily injections. Pet ownership rose sharply during the COVID-19 pandemic, pushing the animal health care market to more than $139
Slide 15: Industry Solution
INDUSTRY SOLUTION Injections are inconvenient for owners and painful for pets. A diabetes pill made from Sirona’s TFC-039 compound solves that problem and keeps pets healthy and happy. Sirona has the solution to address this problem. Top 5 Animal Pharmaceutical Companies and Revenue Merck Boehringer
Slide 16: Facilities/Manufacturing Partner
FACILITIES/MANUFACTURING PARTNER Sirona Biochem Laboratory Manufacturing Partner - TFC-1067 TFChem Laboratory, France WuXi AppTec, China Wanbang Pharma, China The 502-square-meter laboratory is located WuXi AppTec provides a broad R&D and in Val de Reuil, France. This state-of-the-art manufacturing
Slide 17: Technology
TECHNOLOGY Our world-class team is comprised of award-winning scientists who have worked for Fortune 500 companies such as Sanofi, GSK and Bayer. TSX-V: SBM | FSE: ZSB | OTC: SRBCF 17 www.sironabiochem.com
Slide 18: Carbohydrate compounds have immense commercial potential
Carbohydrate compounds have immense commercial potential. • They are involved in many of our body’s biological processes and are also used for development of active ingredients in pharmaceuticals and cosmetics Examples of successful carbohydrate-based drugs are: • Anti-viral medications such as Tami
Slide 19: Increases the potential and reduces the drawbacks
The challenges with carbohydrates are: • Carbohydrates have complex syntheses requiring - Sirona’s Fluorination Chemistry Technology is the solution expert chemists to unstable carbohydrate molecules. • Carbohydrates are unstable, causing lower - The chemistry strengthens the bonds of a carbohydrate
Slide 20: Management
MANAGEMENT Dr. Verrico obtained his medical degree from the University of Toronto in 1985 and has been a member of the College of Physicians and Surgeons of British Columbia since July 1986. Dr. Verrico has extensive experience as a venture capitalist in the junior capital markets. He has acted as a
Slide 21: Christopher Hopton, CPA, CGA
Christopher Hopton, Sirona Biochem’s Chief Financial Officer, brings 28 years of expertise in financial management and operations. His extensive experience covers areas of financial planning, accounting policy and business process improvement. As a business investment and finance consultant, Mr. Hop
Slide 22: Contact Us
CONTACT US Sirona Biochem: Corporate Office TFChem: Laboratory Parent Company - founded 2009 Wholly Owned Subsidiary - acquired in 2011 Sirona Biochem Corp. TFChem c/o WeWork Voie de l’innovation 595 Burrard Street, Pharma Parc II Vancouver, BC 27100 Val de Reuil V7X 1L4 France PHONE: +1.604.641.446
Slide 23: TSX-V: SBM
TSX-V: SBM FSE: ZSB | OTC: SRBCF